Press releases

Initiation of clinical imaging study

29 September, 2021

Annexin Pharmaceuticals and Collaborators Initiate a Clinical Study in Patients with Retinal Vein Occlusion (RVO) Using Fluorescent Labelled ANXV. STOCKHOLM, SWEDEN (September 29, 2021) – Annexin Pharmaceuticals A...

Annexin Pharmaceuticals proposes a fully guaranteed rights issue of units of SEK 73.5 million and has secured further issue proceeds of SEK 17 million in an exercise of the warrants in April 2022

21 September, 2021

 The Board of Directors of Annexin Pharmaceuticals AB (publ) ("Annexin" or "the Company") has today decided to submit a proposal for an Extraordinary General Meeting (“EGM”) in the Company, which is t...

Positive results from Annexin Pharmaceuticals’ phase-1 study

18 September, 2021

The results from Annexin Pharmaceuticals’ phase-1 study show that the drug candidate ANXV was well tolerated by healthy volunteers. The Company thus proceeds with its preparations for a phase-2 study w...

Annexin Pharmaceuticals prepares RVO study in the US

17 August, 2021

Annexin Pharmaceuticals has decided to carry out its phase 2/proof of concept study in RVO in the US. The US is the largest market for RVO, and leading experts in the field can thereby participate in the...

Annexin Pharmaceuticals in collaboration for COVID-19 study

19 May, 2021

Physicians in the Netherlands plan to start a COVID-19 study with Annexin Pharmaceuticals drug candidate ANXV and have to this end submitted an application to the local authority. Annexin Pharmaceuticals...

Regulatory authorities confirm Annexin’s plans in RVO

5 May, 2021

Annexin Pharmaceuticals has conducted successful meetings with regulatory authorities in the United States and Europe. The authorities have confirmed the company’s plans for development of the drug candidate A...